TD Cowen analyst Tara Bancroft lowered the firm’s price target on Vaxcyte (PCVX) to $50 from $85 and keeps a Buy rating on the shares. The firm is confident that VAX-31 in adults should lead to robust immunogenicity and protection, resulting in a large market. In infants, though TD Cowen is heartened that the Phase II is moving forward with an optimized dose, this extends the data timeline to the first half of 2027. The firm remains confident in the success of the adult and infant programs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCVX:
- Vaxcyte’s Strategic Adjustments and Optimized Trials Drive Buy Rating
- Promising Prospects for Vaxcyte’s VAX-31: Strong Adult Trial Results and Strategic Advancements in Infant Studies Reinforce Buy Rating
- Vaxcyte reports Q2 EPS ($1.22), consensus ($1.16)
- Vaxcyte vaccine candidates contain aluminum, says Mizuho
- Vaxcyte Holds Annual Stockholders Meeting on Governance